We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Oxford Nutra Gp | LSE:ONG | London | Ordinary Share | GB00B3LXPB43 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.00 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
TIDMOXP
Oxford Pharmascience Group PLC
20 May 2016
Oxford Pharmascience Group plc
("Oxford Pharmascience" or "the Company")
Presentation at the Shares Magazine Investor Evening (London)
Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, announces that the Company will be presenting at the Shares Magazine Investor Evening being held at the Novotel Tower Bridge, London on Wednesday 25 May 2016.
The Company's CEO, Marcelo Bravo, and the Company's CFO, Chris Hill, will be presenting at the event. Details of the Shares Magazine Investor Evening can be found at http://www.sharesmagazine.co.uk/events/event/shares-investor-evening-25-may-2016.
The presentation has been uploaded to the Company's website at www.oxfordpharmascience.com.
No new material information will be disclosed during the course of the event.
For further information:
Oxford Pharmascience Group Plc
Marcelo Bravo, Chief Executive +44 20 7554 5875
N+1 Singer (Nominated Adviser & Broker)
Aubrey Powell / Jen Boorer +44 20 7496 3000
About Oxford Pharmascience Group Plc
Oxford Pharmascience uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not manufacture or sell its own pharmaceutical products direct to consumers, but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios.
Oxford Pharmascience focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance. By working with such medicines, the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADKLFFQEFLBBZ
(END) Dow Jones Newswires
May 20, 2016 02:00 ET (06:00 GMT)
1 Year Oxford Nutrascience Chart |
1 Month Oxford Nutrascience Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
